TABLE 3.

Comparison Between Patients With and Without Clinical Response to Vedolizumab

Variable	Clinical Response	No Clinical Response	P
	(N = 59)	(N = 24)
Female (n, %)	34 (57.6)	11 (45.8)	0.33
Fistula (n, %)	25 (42.4)	11 (45.8)	0.77
Stricture (n, %)	28 (47.5)	11 (45.8)	0.89
Previous Anti-TNF (n, %)	52 (88.1)	23 (95.8)	0.43
CD features (n, %)	39 (66.1)	15 (62.5)	0.76
Pouchitis ≤1 year after IPAA (n, %) a	16 (28.1)	13 (59.1)	0.01
Obese (n, %)	16 (27.1)	3 (12.5)	0.15
Age <35 years (n, %)	40 (67.8)	15 (62.5)	0.64
Symptoms >5 years (n, %)	24 (42.1)	13 (59.1)	0.18
Smoker (n, %)	13 (22.0)	6 (25.0)	0.77

_a2 patients were missing a vedolizumab initiation date and were excluded from this analysis.